| Ms Michele Jeanne Hathoot, RPH | |
|
2420 Laporte Ave, T1286, Valparaiso, IN 46383-6914 | |
| (219) 531-6628 | |
| (219) 531-6628 |
| Full Name | Ms Michele Jeanne Hathoot |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2420 Laporte Ave, Valparaiso, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295029122 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 26017262A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Michele Jeanne Hathoot, RPH 2420 Laporte Ave, T1286, Valparaiso, IN 46383-6914 Ph: (219) 531-6628 | Ms Michele Jeanne Hathoot, RPH 2420 Laporte Ave, T1286, Valparaiso, IN 46383-6914 Ph: (219) 531-6628 |
News Archive
The HIMSS (Healthcare Information and Management Systems Society) Asia Pac '11 Conference and Exhibition incorporating the HIMAA 2011 National Conference, opened on Tuesday, bringing together leading international experts in healthcare information systems and technology.
Alzheimer's disease is the most representative degenerative brain disease, accounting for 60 to 80% of all dementia cases. In search for new mechanism for AD, the research team led by Professor Seong-Woon Yu of Brain and Cognitive Sciences paid attention to the autophagy of microglia, brain immune cells, is suppressed by inflammation.
Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.
By the time he tested positive for covid-19 on Jan. 12, Gary Herritz was feeling pretty sick. He suspects he was infected a week earlier, during a medical appointment in which he saw health workers who were wearing masks beneath their noses or who had removed them entirely.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.
› Verified 2 days ago
Ms. Cynthia Anne Treble, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1313 Peachtree Dr, Valparaiso, IN 46383 Phone: 708-227-0651 | |
Samantha Salas, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2420 Laporte Ave, Valparaiso, IN 46383 Phone: 219-531-6628 Fax: 219-707-8582 | |
Ms. Christine Monanteras, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2420 Laporte Ave, Valparaiso, IN 46383 Phone: 219-531-6628 Fax: 219-531-6628 | |
Andrew M Baker, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1903 Calumet Ave., Valparaiso, IN 46383 Phone: 219-462-6172 | |
Patricia Bianco, R. PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1903 Calumet Ave, Valparaiso, IN 46383 Phone: 219-462-6172 | |
Mr. Mark Sundh, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Sturdy Rd, Valparaiso, IN 46383 Phone: 219-462-7133 | |
Jacob David Zanolla, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Sturdy Rd, Valparaiso, IN 46383 Phone: 219-462-7173 |